Published in J Neurooncol on August 29, 2017
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 10.56
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
SOX2 functions to maintain neural progenitor identity. Neuron (2003) 7.48
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet (2001) 6.96
SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science (2001) 5.49
Evolution of the cancer stem cell model. Cell Stem Cell (2014) 4.38
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell (2014) 4.04
Protein-tyrosine phosphatases and cancer. Nat Rev Cancer (2006) 3.65
SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells (2009) 3.54
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev (2008) 2.74
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood (2006) 2.28
Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A (2013) 2.25
Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res (1999) 2.16
A role for the scaffolding adapter GAB2 in breast cancer. Nat Med (2005) 2.12
Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol (2000) 1.94
A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol Cell Biol (1997) 1.77
Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol Syst Biol (2009) 1.77
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res (2010) 1.58
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature (2016) 1.52
Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells. PLoS Biol (2015) 1.51
Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol Cell Biol (2007) 1.48
Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem (2005) 1.32
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest (2011) 1.16
Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol Cell Biol (2004) 1.15
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res (2007) 1.08
Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res (2013) 1.08
The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp Cell Res (2009) 1.02
SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res (2004) 0.97
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest (2014) 0.97
Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs). Oncogene (2000) 0.94
miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neurooncol (2015) 0.90
Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis. FASEB J (2012) 0.89
The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells. Cell Death Differ (2015) 0.87
Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression. Cancer Res (2014) 0.86
Clonal evolution of glioblastoma under therapy. Nat Genet (2016) 0.85
Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Reports (2015) 0.84
Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Neuro Oncol (2015) 0.83
Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells. J Cell Sci (2014) 0.82
SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Oncogene (2016) 0.80
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Breast Cancer Res (2016) 0.78
Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. Br J Cancer (2011) 0.78
Hirudin inhibits cell growth via ERK/MAPK signaling in human glioma. Int J Clin Exp Med (2015) 0.76